Zalutsky M R, Archer G E, Garg P K, Batra S K, Bigner D D
Department of Radiology, Duke University Medical Center, Durham, North Carolina 27710, USA.
Nucl Med Biol. 1996 May;23(4):449-58. doi: 10.1016/0969-8051(96)00021-2.
When labeled using the Iodogen method, a chimeric antibody composed of the human IgG2 constant region and the variable regions of murine anti-tenascin 81C6 exhibited superior uptake in human glioma xenografts compared with its murine parent. In the current study, three paired-label experiments were performed in athymic mice with subcutaneous D-54 MG human glioma xenografts to evaluate further the properties of radioiodinated chimeric 81C6. These studies demonstrated that (a) the enhanced tumor uptake of chimeric 81C6 is specific; (b) when labeling was performed using N-succinimidyl 3-iodobenzoate, chimeric 81C6 again showed preferential accumulation in tumor compared with murine 81C6; and (c) the tumor uptake advantage observed previously with murine 81C6 for N-succinimidyl 3-iodobenzoate compared with Iodogen labeling did not occur with chimeric 81C6.
当采用碘甘法进行标记时，一种由人IgG2恒定区和鼠抗腱生蛋白81C6可变区组成的嵌合抗体，与其鼠源亲本相比，在人胶质瘤异种移植瘤中表现出更高的摄取率。在本研究中，对无胸腺小鼠皮下接种D - 54 MG人胶质瘤异种移植瘤进行了三项配对标记实验，以进一步评估放射性碘化嵌合81C6的特性。这些研究表明：(a) 嵌合81C6在肿瘤中的摄取增强具有特异性；(b) 当使用3 - 碘苯甲酸N - 琥珀酰亚胺酯进行标记时，与鼠源81C6相比，嵌合81C6再次显示出在肿瘤中的优先蓄积；(c) 与碘甘标记相比，鼠源81C6先前观察到的对3 - 碘苯甲酸N - 琥珀酰亚胺酯的肿瘤摄取优势在嵌合81C6中未出现。
